For the Long-Term Prevention of Viral Respiratory Tract Infections During Covid-19 Pandemic: A Randomized, Open, Controlled, Exploratory Clinical Study

Overview

Journal Front Pharmacol

Date 2022 May 13

PMID 35559249

Authors

Emil Kolev

Lilyana Mircheva

Michael R Edwards

Sebastian L Johnston

Krassimir Kalinov

Rainer Stange

Giuseppe Gancitano

Wim Vanden Berghe

Samo Kreft

Affiliations

Soon will be listed here.

Abstract

SARS-CoV-2 vaccination is effective in preventing severe Covid-19, but efficacy in reducing viral load and transmission wanes over time. In addition, the emergence of novel SARS-CoV-2 variants increases the threat of uncontrolled dissemination and additional antiviral therapies are urgently needed for effective containment. In previous studies demonstrated strong antiviral activity against enveloped viruses, including SARS-CoV-2. In this study, we examined the potential of in preventing and treating respiratory tract infections (RTIs) and in particular, SARS-CoV-2 infections. 120 healthy volunteers (m,f, 18-75 years) were randomly assigned to prevention or control group without any intervention. After a run-in week, participants went through 3 prevention cycles of 2, 2 and 1 month with daily 2,400 mg extract (Echinaforce, EF). The prevention cycles were interrupted by breaks of 1 week. Acute respiratory symptoms were treated with 4,000 mg EF for up to 10 days, and their severity assessed a diary. Naso/oropharyngeal swabs and venous blood samples were routinely collected every month and during acute illnesses for detection and identification of respiratory viruses, including SARS-CoV-2 RT-qPCR and serology. Summarized over all phases of prevention, 21 and 29 samples tested positive for any virus in the EF and control group, of which 5 and 14 samples tested SARS-CoV-2 positive (RR = 0.37, Chi-square test, = 0.03). Overall, 10 and 14 symptomatic episodes occurred, of which 5 and 8 were Covid-19 (RR = 0.70, Chi-square test, > 0.05). EF treatment when applied during acute episodes significantly reduced the overall virus load by at least 2.12 log or approx. 99% (-test, < 0.05), the time to virus clearance by 8.0 days for all viruses (Wilcoxon test, = 0.02) and by 4.8 days for SARS-CoV-2 ( > 0.05) in comparison to control. Finally, EF treatment significantly reduced fever days (1 day vs 11 days, Chi-square test, = 0.003) but not the overall symptom severity. There were fewer Covid-19 related hospitalizations in the EF treatment group ( = 0 vs = 2). EF exhibited antiviral effects and reduced the risk of viral RTIs, including SARS-CoV-2. By substantially reducing virus loads in infected subjects, EF offers a supportive addition to existing mandated treatments like vaccinations. Future confirmatory studies are warranted.

Citing Articles

Herbal and Dietary Supplements as Adjunctive Treatment for Mild SARS-CoV-2 Infection in Italy.

Licata A, Seidita A, Como S, de Carlo G, Cammilleri M, Bonica R Nutrients. 2025; 17(2).

PMID: 39861359 PMC: 11767322. DOI: 10.3390/nu17020230.

Critical analysis of Echinacea preparations marketed in Germany.

Gross C, Seifert R Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39607548 DOI: 10.1007/s00210-024-03634-2.

Exploring the potency of polyphenol-rich blend from var. sevast., , and : Promising anti-inflammatory, antioxidant, and antiviral properties.

Zima K, Khaidakov B, Sochocka M, Ochnik M, Lemke K, Kowalczyk P Heliyon. 2024; 10(15):e35630.

PMID: 39170264 PMC: 11336823. DOI: 10.1016/j.heliyon.2024.e35630.

Echinacea Reduces Antibiotics by Preventing Respiratory Infections: A Meta-Analysis (ERA-PRIMA).

Gancitano G, Mucci N, Stange R, Ogal M, Vimalanathan S, Sreya M Antibiotics (Basel). 2024; 13(4).

PMID: 38667040 PMC: 11047471. DOI: 10.3390/antibiotics13040364.

Volatile Composition, Antimicrobial Activity, and In Vitro Innate Immunomodulatory Activity of (L.) Moench Essential Oils.

Dosoky N, Kirpotina L, Schepetkin I, Khlebnikov A, Lisonbee B, Black J Molecules. 2023; 28(21).

PMID: 37959750 PMC: 10647913. DOI: 10.3390/molecules28217330.

References

Rotbart H, Hayden F . Picornavirus infections: a primer for the practitioner. Arch Fam Med. 2000; 9(9):913-20. DOI: 10.1001/archfami.9.9.913. View

Ogal M, Johnston S, Klein P, Schoop R . Echinacea reduces antibiotic usage in children through respiratory tract infection prevention: a randomized, blinded, controlled clinical trial. Eur J Med Res. 2021; 26(1):33. PMC: 8028575. DOI: 10.1186/s40001-021-00499-6. View

Thompson M, Burgess J, Naleway A, Tyner H, Yoon S, Meece J . Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December.... MMWR Morb Mortal Wkly Rep. 2021; 70(13):495-500. PMC: 8022879. DOI: 10.15585/mmwr.mm7013e3. View

Mizrahi B, Lotan R, Kalkstein N, Peretz A, Perez G, Ben-Tov A . Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine. Nat Commun. 2021; 12(1):6379. PMC: 8569006. DOI: 10.1038/s41467-021-26672-3. View

Ritchie M, Gertsch J, Klein P, Schoop R . Effects of Echinaforce® treatment on ex vivo-stimulated blood cells. Phytomedicine. 2011; 18(10):826-31. DOI: 10.1016/j.phymed.2011.05.011. View

Ong S, Chiew C, Ang L, Mak T, Cui L, Toh M . Clinical and Virological Features of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern: A Retrospective Cohort Study Comparing B.1.1.7 (Alpha), B.1.351 (Beta), and B.1.617.2 (Delta). Clin Infect Dis. 2021; 75(1):e1128-e1136. PMC: 8522361. DOI: 10.1093/cid/ciab721. View

Sharma M, Anderson S, Schoop R, Hudson J . Induction of multiple pro-inflammatory cytokines by respiratory viruses and reversal by standardized Echinacea, a potent antiviral herbal extract. Antiviral Res. 2009; 83(2):165-70. DOI: 10.1016/j.antiviral.2009.04.009. View

van Elden L, Sachs A, van Loon A, Haarman M, van de Vijver D, Kimman T . Enhanced severity of virus associated lower respiratory tract disease in asthma patients may not be associated with delayed viral clearance and increased viral load in the upper respiratory tract. J Clin Virol. 2007; 41(2):116-21. PMC: 7172053. DOI: 10.1016/j.jcv.2007.10.028. View

Fendrick A, Monto A, Nightengale B, Sarnes M . The economic burden of non-influenza-related viral respiratory tract infection in the United States. Arch Intern Med. 2003; 163(4):487-94. DOI: 10.1001/archinte.163.4.487. View

10.

Signer J, Jonsdottir H, Albrich W, Strasser M, Zust R, Ryter S . Author Correction: In vitro virucidal activity of Echinaforce, an Echinacea purpurea preparation, against coronaviruses, including common cold coronavirus 229E and SARS-CoV-2. Virol J. 2020; 17(1):172. PMC: 7649903. DOI: 10.1186/s12985-020-01439-2. View

11.

Declerck K, Perez Novo C, Grielens L, Van Camp G, Suter A, Vanden Berghe W . Echinacea purpurea (L.) Moench treatment of monocytes promotes tonic interferon signaling, increased innate immunity gene expression and DNA repeat hypermethylated silencing of endogenous retroviral sequences. BMC Complement Med Ther. 2021; 21(1):141. PMC: 8114977. DOI: 10.1186/s12906-021-03310-5. View

12.

Levine-Tiefenbrun M, Yelin I, Katz R, Herzel E, Golan Z, Schreiber L . Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. Nat Med. 2021; 27(5):790-792. DOI: 10.1038/s41591-021-01316-7. View

13.

Jawad M, Schoop R, Suter A, Klein P, Eccles R . Safety and Efficacy Profile of Echinacea purpurea to Prevent Common Cold Episodes: A Randomized, Double-Blind, Placebo-Controlled Trial. Evid Based Complement Alternat Med. 2012; 2012:841315. PMC: 3457740. DOI: 10.1155/2012/841315. View

14.

Vimalanathan S, Shehata M, Sadasivam K, Delbue S, Dolci M, Pariani E . Broad Antiviral Effects of against SARS-CoV-2 Variants of Concern and Potential Mechanism of Action. Microorganisms. 2022; 10(11). PMC: 9694187. DOI: 10.3390/microorganisms10112145. View

15.

Wolff D, Nee S, Hickey N, Marschollek M . Risk factors for Covid-19 severity and fatality: a structured literature review. Infection. 2020; 49(1):15-28. PMC: 7453858. DOI: 10.1007/s15010-020-01509-1. View

16.

Lurie N, Saville M, Hatchett R, Halton J . Developing Covid-19 Vaccines at Pandemic Speed. N Engl J Med. 2020; 382(21):1969-1973. DOI: 10.1056/NEJMp2005630. View

17.

Goldberg Y, Mandel M, Bar-On Y, Bodenheimer O, Freedman L, Haas E . Waning Immunity after the BNT162b2 Vaccine in Israel. N Engl J Med. 2021; 385(24):e85. PMC: 8609604. DOI: 10.1056/NEJMoa2114228. View

18.

Wang Y, Chen R, Hu F, Lan Y, Yang Z, Zhan C . Transmission, viral kinetics and clinical characteristics of the emergent SARS-CoV-2 Delta VOC in Guangzhou, China. EClinicalMedicine. 2021; 40:101129. PMC: 8435265. DOI: 10.1016/j.eclinm.2021.101129. View

19.

Nicolussi S, Ardjomand-Woelkart K, Stange R, Gancitano G, Klein P, Ogal M . as a Potential Force against Coronavirus Infections? A Mini-Review of Randomized Controlled Trials in Adults and Children. Microorganisms. 2022; 10(2). PMC: 8879308. DOI: 10.3390/microorganisms10020211. View

20.

Pouwels K, Pritchard E, Matthews P, Stoesser N, Eyre D, Vihta K . Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nat Med. 2021; 27(12):2127-2135. PMC: 8674129. DOI: 10.1038/s41591-021-01548-7. View